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Abstract
Background: Thrombospondin-1 (TSP-1) is an extracellular matrix component glycoprotein, which is known to
be a potent inhibitor of angiogenesis and may be important in cancer invasiveness. We examined the TSP-1
expression in correlation with conventional clinicopathological parameters to clarify its prognostic significance in
bladder cancer. In addition, the possible correlation of TSP-1 expression with microvessel count, VEGF
expression, p53 expression as well as with the expression of the extracellular matrix components was studied to
explore its implication in vascularization and tumour stroma remodeling.
Methods: The immunohistochemical expression of TSP-1 in tumour cells and in the tumour stroma was studied
in 148 formalin-fixed paraffin-embedded urothelial cell carcinoma tissue samples.
Results: TSP-1 was detected in perivascular tissue, at the epithelial-stromal junction, in the stroma and in tumour
cells in the majority of the cases. In tumour cells, low TSP-1 expression was observed in 43% of the cases,
moderate and high in 7%, while 50% showed absence of TSP expression. A higher TSP-1 immunoreactivity in well
and moderately differentiated tumours compared to poorly differentiated was noted. PT1 tumours showed
decreased TSP-1 expression in comparison to pTa and pT2–4 tumours. Increased tumour cell TSP-1 expression
was related to increased microvessel density. In the tumour stroma, 37% of the cases showed small amount of
TSP-1 expression, 7.5% moderate and high, while 55% of the cases showed absence of TSP-1 stromal
immunoreactivity. Stromal TSP-1 expression was inversely correlated with tumour stage and tumour size. This
expression was also positively correlated with microvessel density, VEGF expression and extracellular matrix
components tenascin and fibronectin. Using univariate and multivariate analysis we didn't find any significant
correlation of TSP-1 expression in superficial tumours in both tumour cells and tumour stroma in terns of the
risk of recurrence and disease progression
Conclusion: Our data suggest that both tumour and stromal TSP-1 expression may play a role in tumour
aggressiveness and angiogenesis. In addition, the correlation of stromal TSP-1 expression with extracellular matrix
components fibronectin and tenascin indicate its possible implication in tumour stroma remodeling.
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Thrombospondins (TSPs) are a family of extracellular pro-
teins recognized as an endogenous constituent of the
extracellular matrix (ECM) in many human tissues. They
are adhesive proteins that promote cell-cell and cell-
matrix interactions [1]. TSPs consists of five subtypes
encoded by independent genes, in which TSP-1 and TSP-
2 contain type-1 repeated with anti-angiogenic activity
[2,3]. Five family members, each representing a separate
gene product, probably exist in most vertebrate species.
Each of these five proteins has a specific pattern of expres-
sion in embryonic and adult tissues with most tissues
expressing at least one family member. Thrombospondin-
1 the first family member to be identified, is a 450-kd
adhesive glycoprotein that was initially discovered in
platelets [4] and subsequently in a variety of cell types
including endothelial cells, fibroblasts, smooth muscle
cells, keratinocytes, macrophages and neutrophils [5]. TSP
has implicated in the regulation of cell growth and prolif-
eration [6], cell motility [7,8] cytosceletal organization
[9], inflammation and wound healing [10], and the devel-
opment and differentiation of cell types [11,12].
Research has demonstrated that both oncogene activation
and loss of tumour-suppressor gene expression are
directly or indirectly related with a decrease in TSP expres-
sion. This could increase the likelihood of the tumour
gaining and the capacity to induce blood vessel forma-
tion, thereby making the 'angiogenic switch' and progress-
ing towards greater malignancy [13,14].
Stromal components also play a critical and often under-
appreciated role in the formation of vascular stroma
through the regulation of functions such as cell adhesion,
migration, and gene expression by controlling the availa-
bility of growth factors [15].
In bladder cancer, it has been found that secretions from
its cancer cells stimulate angiogenesis whereas those from
normal urothelial cells are inhibitory [16]. In addition, it
has been reported that, reduced thrombospondin-1
expression is associated with disease recurrence, decreases
survival and disease progression [14,17].
The objective of the present study was to demonstrate
immunohistochemically the patterns of thrombospon-
din-1 expression in bladder cancer tissues and to define its
prognostic significance and to establish any relationship
with standard clinicopathological features (grade, stage,
concurrent in situ Ca, multifocality, recurrence rate, pro-
gression to muscle infiltrating disease). The alterations
identified have been further correlated with tissue neovas-
cularization (microvessel density-MVD), assessed by
CD34, vascular endothelial growth factor (VEGF) expres-
sion, p53 expression as well as with the expression of the
extracellular matrix (ECM) components tenascin (TN)
and fibronectin (FN) in order to elucidate their interrela-
tionships and the possible role of this protein in tumour
stroma remodeling and angiogenesis.
Methods
Patients
Tumour specimens were obtained transurethrally from
148 patients (119 males and 29 females) aged from 27 to
89 years (mean 66.7 years) and were studied retrospec-
tively. All the patients gave their consent and the investi-
gation was approved by the Hospital Ethic committee.
Biopsies near to and distant from the tumour were also
studied. Bladder wall biopsies from patients undergoing
transurethral prostatectomy were used as controls. The
histopathological diagnosis was made on paraffin sec-
tions stained with haematoxylin and eosin. Histological
grading and staging was performed in accordance with the
guidelines of the International Union Against Cancer
[18]. Seventy five patients presented with pTa disease, 57
patients with pT1 disease and 16 patients with pT2–T4
muscle infiltrating lesions. Seventy four patients from
those with superficial tumours had single, 58 presented
with multiple, 109 with primary while 29 with recurrent
tumours. Tumours of well differentiated (grade 1) were
detected in 6 patients, moderately differentiated (grade 2)
in 78 patients, whereas 64 patients were found with grade
3 disease. Coexistence of carcinoma in situ, in the adjacent
mucosa was found in 21 cases. From the 132 patients with
superficial tumours 113 were followed up for maximum
69 months. Eighty patients from these subsequently went
on to tumour recurrence whilst 33 did not. Tumour pro-
gression (defined as the presence of muscle invasion,
stage pT2 or higher in a subsequent biopsy) was found in
8 cases. Patients with superficial bladder cancer were fol-
low up and were part of another protocol studying [19]
interferon gamma and categorized into two groups: one
group that received only transurethral resection (TURT)
(48 patients) and in the other resection was followed by
intravesical instillations of interferon gamma (IFN) (65
patients). In 8 patients cystectomy was performed. The
times to first recurrence and progression were recorded
during the follow-up period (minimum 3, maximum 68,
median 12 months to first recurrence and minimum 3,
maximum 69, median 31 months to progression). Fol-
low-up consisted of a biochemical profile, chest radiogra-
phy, and a physical examination. Cystoscopy was
conducted every three months for one year, every six
months for 2 years and yearly thereafter.
Immunohistochemistry
For immunohistochemical staining, additional 4 μm
thick sections were cut from paraffin-embedded tissue
placed on poly-L-lysine-coated glass slides. In brief, sec-
tions were deparaffinised in xylene and rehydrated. ForPage 2 of 8
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were immersed in citrate buffer (0.1 m, pH 0.6) in plastic
Coplin jars and subjected to microwave irradiation twice
for 15 min. Subsequently, all sections were treated for 30
min with 0.3% hydrogen peroxide in methanol to quench
endogenous peroxidase activity and then incubated with
primary antibodies. We used the method involving the
avidin-biotin-peroxidase complex and developed the
chromogen with immersion of the slides in a diami-
nobenzidine-H2O2 substrate for 5 min. The slides were
counterstained in Harris' haematoxylin, dehydrated and
mounted. To assess the specificity of the reaction, negative
controls were included, where tumour sections subjected
to the whole procedure except for incubation without the
primary antibody. Positive control slides were also exam-
ined in each experiments. The antibodies sources and
dilutions are shown in Table 1.
Immunohistochemical assessment
Thrombospondin-1 and VEGF
To evaluate the expression of TSP-1 and VEGF proteins,
we established a combined score, corresponding to the
sum of both (a) staining intensity (0 = negative, 1 = weak,
2 = intermediate, 3 = strong, 4 = very strong staining) and
(b) the staining extensive, percentage of positive cells (0 =
0%, 1 = 1–25%, 2 = 26–50%, 3 = 50–75%, 4 = >75%). The
sum of both qualitative and quantitative immunostaining
reached a maximum score of 8. The combined scores were
then divided into 4 main groups: (-) = no immunostain-
ing, score 0, (+) = weak immunostaining, scores 1–2, (++)
= moderate immunostaining, scores 3–4, (+++) = strong
immunostaining, scores 5–8.
Extracellular matrix components
the evaluation of TN and FN, the tumours were classified
as 'positive' when there was unequivocal immunostaining
of the matrix components in at least one representative
area of the tumour. The positive tumours were semi-quan-
titatively scored as +, ++, and +++ corresponding to weak,
moderate and extensive immunoreactivity respectively.
p53 protein
Nuclear staining for p53 was calculated as the percentage
of positive epithelial cell in relation to the total number of
neoplastic cells. Every stained cell was considered positive
irrespective of intensity. Each sample was first scanned on
low magnification and at least 5 representative fields were
assessed with a high power magnification.
Microvessel count
The criteria that we used for microvessel recognition were
the same as used in previous studies. Briefly, as microves-
sels we considered individual or clusters of cells with or
without lumens, positively stained by anti-CD34. The
lumen diameter had to be smaller than approximately
eight red blood cells. Areas of fibrosis, necrosis and
inflammation, and vessels with muscle wall were
excluded from counting. In each tumour, the three areas
with the highest vascularization ("hot spot") were
selected. Individual microvessel counts were then made
on a 250 X field (25 X objective and 10 X ocular, corre-
sponding to an area of 0.363 mm2).
The immunoreactivity was interpreted by means of light-
microscopic examination and evaluated independently by
two pathologists (EI, MM). Differences in interpretation
were reconciled by re-review of slides separately or jointly
at a double-headed microscope. The staining was evalu-
ated only in the areas with well-preserved tissue morphol-
ogy and away from necrosis or artefacts. The
immunostaining was assessed from numerically coded
slides without any knowledge of survival or other clinical
data.
Statistics
Superior Performance Software System (SPSS) software
10.0 for windows (SPSS Inc., 1989–1999) was used by the
authors to compare morphological features and protein
expression data. Significant differences between the
expression of the target proteins with regard to clinico-
pathological parameters were computed by the t-test for
paired or non-paired values or ANOVA test if the data
were normally distributed. Correlation between these
proteins was computed using the Pearson's correlation
Table 1: Antibodies used
Antibodies Supplier Dilution Incubation time
TSP-1(A6.1)* DBS 1:30 30 min
VEGF* Dako 1:50 1 hour
CD34(QBEnd/10) Novo Castra 1:50 1 hour
Tenascin (TN2)# Dako 1:50 1 hour
Fibronectin (clone, 568)# Novo Castra 1:100 1 hour
P53 (DO-7)* Dako 1:50 1 hour
*with microwave oven antigen retrieval
# incubation with pronasePage 3 of 8
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Tau rank correlation coefficient where the data did not
show a normal distribution. The prognostic significance
of thrombospondin-1 expression, in determining the risk
for recurrence, was studied with both univariate (log rank
test) and multivariate (Cox proportional hazards) ways of
analysis, separately for each group of patients. P-values ≤
0.05 were considered statistically significant.
Results
In urothelial cell carcinomas, TSP-1 was detected in the
perivascular tissue, at the epithelial-stromal junction, in
the stroma and in tumour cells (Fig. 1) in the majority of
the cases
In tumour cells, low TSP-1 expression was observed in 64/
148 (43.2%) of the cases, a moderate and high in 10/148
(6.8%), while 74/148 (50%) showed an absence of TSP-1
expression. Poorly differentiated tumours showed lower
TSP-1 expression in tumour cells compared to the well
and moderately differentiated ones (p = 0.038) (Table 2).
PT1 tumours showed decreased TSP expression in compar-
ison to pTa and PT2–4 (p = 0.005) and (p = 0.021) respec-
tively (Table 2). A strong positive relationship of tumour
cell TSP-1 expression with MVD (p < 0.0001) was also
observed (Table 3).
In tumour stroma, 55/147 (37.4%) of the cases showed
small amount of TSP-1 expression, 11/147 (7.5%) mod-
erate and high, while 81/147 (55.1%) of the cases showed
an absence of TSP-1 stromal immunoreactivity. PT2–4
tumours showed higher stromal TSP-1 expression com-
pared to PTa (p = 0.033) and PT1 (p = 0.013) (Table 2). In
addition, larger tumours (>3 cm) showed higher stromal
TSP-1 expression (p = 0.021) (Table 2). This expression
was also positively correlated with MVD (p = 0.031) and
VEGF expression (p = 0.001) as well as with both extracel-
lular matrix components tenascin (p < 0.0001) and
fibronectin. (p = 0.003) (Table 3). A positive relationship
between expression of TSP-1 in tumour cells and stroma
was observed (p = 0.038) for each case.
Tumour and stromal TSP-1 expression did not correlated
with p53 protein expression (Table 3). In addition,
tumour and stromal TSP-1 expression did not correlate
with the concurrent in situ element, multifocality, pri-
mary or recurrent status. The prognostic significance of
TSP-1 expression in superficial tumours in both tumour
cells and tumour stroma in determining the risk of recur-
rence and progression with univariate and multivariate
methods of analysis showed no statistically significant dif-
ferences. In addition, this expression did not correlate
with progression to muscle infiltrating disease.
Discussion
Angiogenesis is a multistep process, which involves
changes in the extracellular matrix, and endothelial cell
proliferation, migration, and differentiation into capillar-
ies. Studies of tumour biology reveal a complex network
of autocrine and paracrine interactions between tumour
cells, stromal cells, and endothelial cells, which are in turn
influenced by the composition of the extracellular matrix.
The development of new blood vessels within a tumour
depends upon the local balance between angiogenic and
anti-angiogenic factors. The induction of angiogenesis has
an important role in the pathogenesis of bladder cancer
[16]. Microvessel density has been correlated strongly
with advanced pathological findings and poor outcomes
in patients with bladder cancer [20,21] and drugs with
anti-angiogenic activity have blocked by bladder tumour
progression in the experimental models [22,23]. Down-
regulation of the secretion of TSP-1 was found to be a key
Table 2: Tumour and stromal TSP expression in correlation with clinicopathological data
tumour cells TSP stromal TSP
0,1/2,3 p value 0/+,++,+++ p value
grade
1 6 1 2 5
2 71 6 p = 0.038 38 37 NS
3 58 6 39 26
Stage
pTa 69 5 39 35
pT1 53 3 p = 0.005 34 21 p = 0.033
pT2–4 12 6 p = 0.021 6 12 P = 0.013
size
<3 cm 71 8 NS 45 33 p = 0.021
>3 cm 36 2 15 28
Single 67 7 38 36
multiple 62 3 NS 36 28 NS
no in situ 110 10 63 56
in situ 21 - NS 12 9 NSPage 4 of 8
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iogenic phenotype during bladder tumorigenesis [16].
The results of the present study showed a relationship of
tumour cells TSP-1 expression with tumour grade, accord-
ing to the findings of other studies in bladder cancer and
in other types of tumours [14,24,25]. Similarly, an
increase TSP-1 expression, by tumour cells has been found
to be correlated with a reduced metastatic potential in
experimental tumours, formed from melanoma, lung,
and breast carcinoma cell lines [26]. In addition, we also
found an inverse relationship of stromal TSP-1 with
tumour stage. It is possible that this might indicate the
switch to an angiogenic phenotype in invasive tumours
and support the association between stromal TSP-1 loss
and a more aggressive phenotype. In contrast, pT1
tumours showed a lower TSP-1 expression in tumour cells
compared to pTa and pT2–4. This phenomenon possibly
reflect different stage of TSP-1 production by tumour or
stromal cell according to various environmental or intrin-
sic factors.
A relevant immunohistochemical study reported by
Grossfeld et al [14] showed that patients with low TSP-1
expression exhibited increased recurrence rates and
decreased overall survival. In this study it was found that
TSP-1 was an independent predictor of disease recurrence
and overall survival after stratifying for tumour stage,
lymph node status, and histological grade, but it was not
independent of the p53 status. In addition, Goddard et al
[17] observed that reduced perivascular TSP-1 staining at
presentation was an independent predictive factor for the
subsequent development of muscle invasive or metastatic
disease. In the current study, we found no association of
TSP-1 expression and recurrence rate or in the progression
of muscle invasive tumour. These discrepancies are possi-
ble due to the different antibodies used, or to difficulties
in quantification within a friable papillary tumour or dif-
ferences in the behavior of tumour tissue microenviron-
ment from case to case. In the study, of Grossfeld et al [14]
the antibody used was the mouse anti-TSP monoclonal
antibody MA-II that recognizes an epitope in the amino-
terminal region of TSP-1, while in the study of Goddard
JC et al [17] used monoclonal antibody against TSP-1(Ab-
4). In the present study we used a monoclonal mouse
antibody to thrombospondin clone A6.1. Grossfeld et al
[14] also found that decreased levels of TSP-1 staining
were correlated with increased MVD and increasing p53
mutation. We found a positive correlation of tumour and
stromal TSP-1 expression with MVD and a strong relation-
ship of stromal TSP-1 expression with tumour VEGF
Tumour and stromal TSP-1 expression in a case of infiltrating urothelial bladder carcinoma (o iginal magnification ABCX 200)Figur  1
Tumour and stromal TSP-1 expression in a case of infiltrating 
urothelial bladder carcinoma (original magnification ABCX 
200).
Table 3: Tumour and stromal TSP expression in correlation with MVD, VEGF expression and ECM components
tumour cells TSP stromal TSP
0,1/2,3 p value 0/+,++, +++ p value
mvd
low 57 3 p < 0.000 36 24 p = 0.031
high 55 5 1 23 37
VEGF
low(0,1) 30 2 NS 24 8 p = 0.001
high (2,3) 100 8 51 56
p53
<5% 40 5 NS 37 17 NS
>5% 44 4 29 19
tenascin
0,+ 70 6 NS 56 19 p < 0.000
++,+++ 23 3 9 17 1
fibronectin
0,+ 39 3 NS 32 10 p = 0.003
++,+++ 54 6 33 26Page 5 of 8
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ity which is involved in the interaction of the microvascu-
lar endothelial cell receptor CD36 [27], in the present
study we found TSP-1 as inducer of microvascularity. The
role played by TSP-1 in the regulation of angiogenesis is
not clear. Positive and negative effects of TSP-1 on angio-
genesis have been reported. It has previously been shown
that this protein may be inhibitory to angiogenesis both
in vivo and vitro studies [2,28,29]. In contrast to these
findings, a recent study by Nicosia and Tusznyski [30], has
suggest that matrix-bound thrombospondin-1 may indi-
rectly promoting angiogenesis in vitro. In addition, Ben
Ezra et al [31] has shown that TSP-1 enhances the induc-
tion of angiogenesis by either bFGF or bacterial endotoxin
lipopolysaccharide using the rabbit cornea assay.
It is now well established that the activation of oncogenes
or inactivation of tumour suppressor genes may directly
influence the angiogenic phenotype by altering the rela-
tive amounts of inducers and inhibitors secreted by the
tumour, in addition to their effect on proliferation and
apoptosis [32]. It has been reported that there is a link
between TSP-1 expression, tumour angiogenesis, and the
p53 tumour suppressor gene status and it has been dem-
onstrated that in fibroblasts, that wild type p53 inhibits
angiogenesis through the up-regulation of TSP synthesis
[33]. Volpert et al [34] showed that mutation or inactiva-
tion of p53 in fibrosarcoma leads to the down-regulation
of TSP-1 and enhanced expression of VEGF, tipping the
balance in favor of angiogenesis. Environmental factors
such as relative hypoxia, within the microenvironment of
most tumors, including bladder cancer, may also influ-
ence the expression of angiogenic mediators, most nota-
bly VEGF[35]. It has also been hypothesized that hypoxia
may regulate TSP-1, VEGF and angiogenic activity in blad-
der cancer [36]. In the present study we found no relation-
ship between TSP-1 and p53 protein expression. Our
results could suggest that p53 does not act as primary reg-
ulator of angiogenesis in bladder cancer. Such a clear-cut
association might not be a general feature for all tumour
types. Analysis of certain cancers, such as lung cancer,
cholangiocarcinoma, and glioblastoma, found no associ-
ation between the presence of p53 alterations and TSP-1
expression [37-40] in line with our results.
The composition of the extracellular matrix may be mod-
ified in vivo in several ways. For example, angiogenic fac-
tors are known to modulate both the synthesis of matrix
proteins [41,42]. As well as the synthesis of certain pro-
teases and their inhibitors [42-44]. To our knowledge
there are no reports concerning the correlation between
TSP-1 expression and the extracellular matrix in bladder
cancer. Fibronectins may play an important role in vascu-
lar stroma formation because they have been reported to
be an essential for the heart and blood vessel morphogen-
esis [45], to be chemotactic for endothelial cells [46], to
modulate endothelial response to growth factors [47],
and to promote the elongation of microvessels during
angiogenesis in vitro [48]. TN and FN are glycoprotein
components of the ECM which seem to have competitive
functions. It can be speculated that this competitive rela-
tionship between these molecules is important for cellular
functions [49]. There are evidences that tenascin and TSP-
1 modulate sprouting of endothelial cells [50]. Tenascin
expression indicates an altered cell-ECM interaction that
might facilitate epithelial tumour cell invasion [51,52].
Tenascin expression is highly up-regulated during tumour
invasion in many tumour types, including bladder carci-
nomas [53,54]. In a previous study concerning the expres-
sion of extracellular matrix components in urothelial
carcinoma [55] we found that tenascin and fibronectin
seemed to be correlated with more aggressive tumour
behaviour. In another study [56], we found that extracel-
lular matrix components may be involved in the develop-
ment and progression of breast cancer. In addition,
overexpression of stromal TN and FN seem to have a poor
prognostic value in breast cancer patients. In the present
study we found a strong relationship of TSP-1 expression
with TN and FN suggesting the contribution of these glyc-
oproteins in tumour stroma, remodeling or the effect of
these ECM products in bladder vascularization. The for-
mation of a new vessels is required for tumour progres-
sion and invasion and inhibition of angiogenesis may
affect the early steps of tumour development. So, our data
provide implication of other pathways of the regulation of
TSP-1 and angiogenesis, possibly through the interaction
of ECM components. The ultimate aim is to develop
another modality in targeting anti-angiogenic therapies.
Conclusion
The results of the present study indicate that TSP-1 expres-
sion is not useful for predicting recurrence or progression
to muscle invasive diseases. However, reduction of its
expression appears to be correlated with a more aggressive
phenotypes. In addition, stromal TSP-1 expression seems
to play a role in bladder cancer vascularization possibly in
cooperation with other angiogenic factors. Finally, TSP-1
expression could contribute in bladder cancer tissue
remodeling, possibly in collaboration with other ECM
components.
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